Dr Reddy's Laboratories Income from Continuous Operations 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Dr Reddy's Laboratories income from continuous operations for the quarter ending June 30, 2024 was $0.167B, a 2.34% decline year-over-year.
- Dr Reddy's Laboratories income from continuous operations for the twelve months ending June 30, 2024 was $664M, a 16.7% increase year-over-year.
- Dr Reddy's Laboratories annual income from continuous operations for 2024 was $0.668B, a 21.9% increase from 2023.
- Dr Reddy's Laboratories annual income from continuous operations for 2023 was $0.548B, a 76.21% increase from 2022.
- Dr Reddy's Laboratories annual income from continuous operations for 2022 was $0.311B, a 31.78% increase from 2021.
Dr Reddy's Laboratories Annual Income from Continuous Operations
(Millions of US $) |
| 2024 |
$668 |
| 2023 |
$548 |
| 2022 |
$311 |
| 2021 |
$236 |
| 2020 |
$258 |
| 2019 |
$272 |
| 2018 |
$150 |
| 2017 |
$186 |
| 2016 |
$302 |
| 2015 |
$356 |
| 2014 |
$351 |
| 2013 |
$316 |
| 2012 |
$300 |
| 2011 |
$242 |
| 2010 |
$205 |
| 2009 |
$173 |
Dr Reddy's Laboratories Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$167 |
| 2024-03-31 |
$153 |
| 2023-12-31 |
$165 |
| 2023-09-30 |
$178 |
| 2023-06-30 |
$171 |
| 2023-03-31 |
$107 |
| 2022-12-31 |
$152 |
| 2022-09-30 |
$139 |
| 2022-06-30 |
$150 |
| 2022-03-31 |
$5 |
| 2021-12-31 |
$95 |
| 2021-09-30 |
$134 |
| 2021-06-30 |
$77 |
| 2021-03-31 |
$54 |
| 2020-12-31 |
$3 |
| 2020-09-30 |
$103 |
| 2020-06-30 |
$76 |
| 2020-03-31 |
$87 |
| 2019-12-31 |
$-80 |
| 2019-09-30 |
$155 |
| 2019-06-30 |
$96 |
| 2019-03-31 |
$67 |
| 2018-12-31 |
$67 |
| 2018-09-30 |
$72 |
| 2018-06-30 |
$66 |
| 2018-03-31 |
$45 |
| 2017-12-31 |
$52 |
| 2017-09-30 |
$44 |
| 2017-06-30 |
$9 |
| 2017-03-31 |
$55 |
| 2016-12-31 |
$69 |
| 2016-09-30 |
$44 |
| 2016-06-30 |
$18 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$88 |
| 2015-09-30 |
$111 |
| 2015-06-30 |
$98 |
| 2015-03-31 |
$83 |
| 2014-12-31 |
$91 |
| 2014-09-30 |
$93 |
| 2014-06-30 |
$92 |
| 2014-03-31 |
$80 |
| 2013-12-31 |
$100 |
| 2013-09-30 |
$110 |
| 2013-06-30 |
$61 |
| 2013-03-31 |
$105 |
| 2012-12-31 |
$69 |
| 2012-09-30 |
$77 |
| 2012-06-30 |
$60 |
| 2012-03-31 |
$68 |
| 2011-12-31 |
$97 |
| 2011-09-30 |
$63 |
| 2011-06-30 |
$59 |
| 2011-03-31 |
$75 |
| 2010-12-31 |
$61 |
| 2010-09-30 |
$64 |
| 2010-06-30 |
$45 |
| 2010-03-31 |
$37 |
| 2009-12-31 |
$-112 |
| 2009-09-30 |
$45 |
| 2009-06-30 |
$51 |
| 2009-03-31 |
$-192 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$12.329B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
